Menopause belly fat, PCOS insulin resistance, and metabolic support. From FDA-approved GLP-1 agonists to targeted visceral fat peptides.
Weight management for women is not a willpower issue — it's a hormonal and metabolic reality. Declining estrogen during perimenopause and menopause shifts fat storage from subcutaneous (hips, thighs) to visceral (abdomen), while simultaneously reducing insulin sensitivity and metabolic rate. PCOS compounds this with chronic insulin resistance. Peptide therapy addresses these biochemical drivers directly.
FDA-approved GLP-1 agonist. 15-17% body weight reduction in Phase III trials. Oral formulation launched 2026.
Shop at BioPure → Read Full Profile →Dual GLP-1/GIP agonist. Up to 22.5% weight reduction in SURMOUNT-1 — outperforms semaglutide head-to-head.
Shop at BioPure →FDA-approved GHRH analog. Specifically targets visceral belly fat — the "menopause belly" peptide.
Shop at BioPure → Read Full Profile →HGH fragment targeting fat metabolism without GH side effects. Stimulates lipolysis, inhibits lipogenesis.
Shop at BioPure →Every woman's situation is different. Your life stage, specific symptoms, medical history, and treatment goals all factor into which peptide — or combination of peptides — may be most relevant. We always recommend working with a licensed healthcare provider who has experience with peptide therapy.
Our quiz can help narrow down options based on your individual profile:
Take the Quiz →Medical Disclaimer: This guide is for educational purposes only. It is not medical advice or a treatment recommendation. Peptide therapies discussed may be investigational, off-label, or subject to evolving FDA regulations. Always consult a qualified healthcare provider.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Peptide therapy spans hormones, weight, skin, gut health, mood, energy, and recovery.
View All Use Cases →